Reporting onsite from AACR 2022 in New Orleans, John Haanen explains the results from a phase I study testing CAR T cells targeting Claudin-6 which is a protein not expressed in adult healthy tissue, but in certain ovarian, endometrial and testicular cancers. The study was carried out in patients who had previously failed all treatments. Combined with a CAR T cell amplifying RNA vaccine to prolong the CAR T cells persistence, this novel therapy showed promising early results in terms of response and safety.
Reference:
Haanen J, Mackensen A, Koenecke C, et al. BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors. AACR Annual Meeting 2022; New Orleans, Louisiana, USA: 8–13 April.
ESMO Members, read the Congress Watch article on this study